Diary-based Study on the Course of Hormone-withdrawal Migraines

Overview

Single centered diary-based study to identify course and characteristics of hormone withdrawal headaches/migraines in users of combined hormonal contraceptives Objectives of the Research Project: to identify the course and characteristics of hormone withdrawal headaches/migraines in users of combined hormonal contraceptives (CHC)

Full Title of Study: “Single Centered Diary-based Study to Identify Course and Characteristics of Hormone Withdrawal Headaches/Migraines in Users of Combined Hormonal Contraceptives”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: April 15, 2019

Detailed Description

Participant recruitment is performed through advertisement placed in University Zürich (USZ) online. Advertisement in offices of neurologists and headache specialists, homepage of the Swiss headache society. Interested women contact the investigators via email and are called back by one of the study doctors or students within 1 day from Monday-Friday. This phone call is thought to inform the women about the study in more detail and for the investigators to check eligibility. During this call the participants are informed about the study procedure and can ask any question. Here most important points are use of a CHC in a 21/7 regimen, regular (at least once on two months) withdrawal migraine/headaches, intention to continue the use of the contraceptive for 3 more months. If the participants decide to participate, inclusion and exclusion criteria are checked. If women are applicable they receive the consent form and the study information with an envelope for return. If more questions come up the investigators are available per email and phone for answers. If a patient doesn't return the consent form the investigator will delete the personal data, which collected before. Only the year of birth will be noted in the personal data. After consent participants receive headaches diaries (with mail /post) and a prepaid envelope (for return). Participants are also offered the option to return their diaries electronically via email to the study doctor. Furthermore participants receive in a second phone contact instructions, how to fill in the headache diary and the day of study start (first day of the next pill package). Headache diaries should be returned monthly (per email or post) and are conducted for 3 pill cycles. If complete headache diaries are not returned participants will be contacted per email after 1 week to remind the participants. If this email is not being answered within another week a phone contact will take place to identify potential reasons for noncompliance or withdrawal of consent or drop out. Observation period 3 pill cycles : 3 times 28 days Outcomes of the Research Project: – Daily number of headaches and migraine in each day of the observation cycle.and during the Hormone-free interval (HFI) – First day of migraine in the pill-free interval – Start of migraine in relation to withdrawal bleeding – Start of and number of prolonged migraines >24 hours in the pill-free interval and the phase of hormone intake. – Pain intensity in the pill-free interval in comparison to the pill-phase – Number of rescue medications/ migraine day during HFI and during pill intake – efficacy of the medications (did medication stop the attack and did the attack return after maximal 8 hours) – Within patient variability of the first migraine day in the HFI. Statistical Methodology: – Primary and secondary endpoints will be calculated as frequencies and percentages. – For comparison the number of prolonged attacks during pill use and the HFI prolonged attacks per day of the observation interval are calculated and thereafter chi-square test for comparisons is used . – Software programme is used for data analyses.

Interventions

  • Behavioral: Diary

Arms, Groups and Cohorts

  • premenopausal women
    • diary

Clinical Trial Outcome Measures

Primary Measures

  • Migraine in the pill-free interval
    • Time Frame: up to 3 months
    • Migraine at each day of the pill-free interval

Secondary Measures

  • First migraine day
    • Time Frame: up to 3 months
    • First day of migraine in the pill-free interval
  • migraine episodes
    • Time Frame: up to 3 months
    • Start of migraines >24 hours in the pill-free interval

Participating in This Clinical Trial

Inclusion Criteria

  • Premenopausal women – Age 18-50 years – Use of combined hormonal contraceptives 21/7 regimen – Suffering from headache/migraine in the HFI. – Women are allowed to use their normal headache medications Exclusion Criteria:

  • Withdrawal of consent – incomplete diaries – pregnancy – migraine/headache in only 1 cycle – inability to follow procedures (e.g. due to psychological disorders or dementia), insufficient knowledge of project language).

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 50 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of Zurich
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Gabriele Merki, Professor, Study Director, University Hospital, Zürich

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.